Susquehanna International Group, LLP An2 Therapeutics, Inc. Transaction History

Susquehanna International Group, LLP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 15, 2024	SELL	$1.93 - $3.76 $331,197 - $645,234	-171,605 Reduced 84.6%	31,245 $67,000
Q1 2024 May 07, 2024	BUY	$2.78 - $21.53 $287,579 - $2.23 Million	103,446 Added 104.07%	202,850 $659,000
Q4 2023 Feb 14, 2024	BUY	$13.92 - $21.0 $1.05 Million - $1.58 Million	75,141 Added 309.69%	99,404 $2.04 Million
Q3 2023 Nov 14, 2023	BUY	$7.58 - $16.08 $183,913 - $390,149	24,263 New	24,263 $390,000
Q3 2022 Nov 14, 2022	SELL	$7.61 - $22.29 $77,561 - $227,179	-10,192 Reduced 37.72%	16,827 $292,000
Q2 2022 Aug 15, 2022	BUY	$7.7 - $18.82 $208,046 - $508,497	27,019 New	27,019 $209,000

13.5M

Ticker ANTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 19,402,700
Market Cap $26M
Description
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menl...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.